Microbiome Therapies Market
Microbiome Therapies Market Forecasts to 2032 – Global Analysis By Therapy Type (Live Biotherapeutic Products (LBPs), Fecal Microbiota Transplantation (FMT), Engineered Microbial Consortia, Next-Generation Probiotics, Prebiotics & Postbiotics, and Phage-Based Therapies), Target Area, Technology, Application, End User, and By Geography.
According to Stratistics MRC, the Global Microbiome Therapies Market is accounted for $3.2 billion in 2025 and is expected to reach $14.6 billion by 2032 growing at a CAGR of 24.2% during the forecast period. Microbiome Therapies are treatments designed to modify or restore the microbial ecosystems within the human body to improve health outcomes. These therapies utilize probiotics, engineered bacteria, microbiota transplants, or targeted microbial metabolites to address diseases linked to dysbiosis. They play an expanding role in gastrointestinal disorders, metabolic diseases, immune modulation, oncology, and neurodevelopmental conditions. Advanced analytics enable precision modulation of microbiome interactions, creating personalized therapeutic strategies with fewer side effects compared to conventional drugs.
According to a Strategic Revenue Insights consumer survey, rising awareness of gut health drives 20% annual increase in demand for microbiome therapies, with 62% of respondents prioritizing probiotics for immune and metabolic support.
Market Dynamics:
Driver:
Increasing demand for personalized medicine
Growth is primarily fueled by the increasing demand for personalized medicine. Advanced technologies like artificial intelligence and genomic sequencing are enabling the development of microbiome therapies tailored to an individual's unique microbial composition. This shift from a universal treatment model to a personalized approach significantly enhances therapeutic efficacy for complex conditions such as cancer, metabolic disorders, and autoimmune diseases. This focus on precision health is a key market driver, promising better patient outcomes and driving investment and innovation in the sector.
Restraint:
Complex regulatory pathways for approval
The market faces significant challenges from complex and evolving global regulatory standards. While the U.S. FDA has established a defined pathway for Live Biotherapeutic Products (LBPs), regulatory agencies in Europe and Asia-Pacific are still refining their own guidelines. This lack of harmonization creates uncertainty for manufacturers, leading to extended product approval timelines and significantly higher development costs. Navigating this fragmented and often unsettled regulatory landscape remains a major restraint for companies operating across different international markets.
Opportunity:
Emerging applications in metabolic disorders
Emerging applications in metabolic disorders represent a significant growth opportunity. There is increasing research into the gut microbiome's direct influence on conditions like obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Major initiatives, such as the Novo Nordisk Foundation's Microbiome Health Initiative, are investing heavily to develop novel therapies that modulate the gut microbiota to improve cardiometabolic health. This expanding understanding opens a vast new frontier for therapeutic development beyond traditional gastrointestinal indications.
Threat:
Safety concerns with live microbial products
A key threat involves potential safety concerns associated with live microbial products. Unlike traditional drugs, LBPs contain living organisms, raising unique challenges regarding their stability, interaction with a patient's native microbiome, and the risk of transmitting antibiotic resistance genes. There is also a theoretical risk of infections in immunocompromised patients. These concerns necessitate rigorous long-term safety monitoring and complex manufacturing controls, which can deter investment and complicate regulatory approval, potentially limiting widespread market adoption.
Covid-19 Impact:
The pandemic initially disrupted clinical trials, manufacturing activities, and supply chains, slowing development timelines for several microbiome candidates. However, rising interest in immune resilience and host-microbe interactions stimulated renewed investment and accelerated research post-pandemic. Increased adoption of digital clinical monitoring supported recovery of trial activity. Heightened awareness of microbial health strengthened consumer and clinical interest in microbiome solutions, ultimately positioning the sector for faster growth in the post-COVID landscape despite early operational setbacks.
The live biotherapeutic products (LBPs) segment is expected to be the largest during the forecast period
The live biotherapeutic products (LBPs) segment is expected to account for the largest market share during the forecast period, owing to their broad therapeutic applicability, high clinical investment, and strong evidence demonstrating microbiome modulation benefits. LBPs target diverse conditions ranging from gastrointestinal disorders to immunological and metabolic diseases, creating wide adoption potential. Advances in strain engineering, formulation stability, and precision dosing reinforce their dominance. Growing partnerships between biotech firms and pharmaceutical companies further solidify the segment’s leadership position.
The gut microbiome segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the gut microbiome segment is predicted to witness the highest growth rate, reinforced by extensive research linking gut microbial composition to systemic immunity, metabolic regulation, and neurological health. Strong clinical pipelines, enhanced sequencing technologies, and rising diagnostic integration accelerate therapeutic development. As personalized nutrition, metabolic therapies, and immunomodulatory treatments expand, gut-focused interventions gain momentum. Broad disease applicability and rapid scientific validation position this segment as the fastest-advancing domain within microbiome therapeutics.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, ascribed to increasing biotech investments, expanding clinical research infrastructure, and high prevalence of gastrointestinal and metabolic disorders. Countries such as China, Japan, South Korea, and Singapore exhibit strong regulatory support for microbiome innovation. Rising consumer awareness, growing precision-medicine initiatives, and the presence of advanced sequencing capabilities further accelerate adoption. Robust manufacturing capacity and government-backed R&D programs solidify APAC’s dominant market position.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR associated with strong venture capital influx, advanced clinical trial ecosystems, and rapid commercialization pathways for innovative therapeutics. The U.S. leads with cutting-edge microbiome research, high adoption of precision medicine, and active collaborations between biotech firms, academic centers, and pharmaceutical companies. Growing demand for targeted therapies, supportive FDA initiatives, and expanding multi-omics integration further propel growth, positioning North America as the fastest-expanding market.
Key players in the market
Some of the key players in Microbiome Therapies Market include Seres Therapeutics, Ferring Pharmaceuticals, Vedanta Biosciences, Finch Therapeutics, Synthetic Biologics, 4D Pharma, BiomeBank, Evelo Biosciences, Enterome, Rebiotix (Ferring), Takeda, Johnson & Johnson, Novartis, GSK, Pfizer, Roche and Merck & Co.
Key Developments:
In November 2025, Vedanta progressed Phase II trials of VE303 for recurrent C. difficile infection, leveraging defined bacterial consortia to deliver standardized microbiome therapeutics with improved safety and efficacy profiles.
In October 2025, Seres advanced commercialization of VOWST™, its FDA-approved microbiome therapeutic for recurrent C. difficile infection, expanding distribution partnerships and initiating new clinical trials for ulcerative colitis and oncology indications.
In September 2025, Ferring scaled production of REBYOTA™, the first FDA-approved fecal microbiota therapy, expanding access in North America and Europe while investing in next-generation microbiome-based therapeutics for gastrointestinal disorders.
Therapy Types Covered:
• Live Biotherapeutic Products (LBPs)
• Fecal Microbiota Transplantation (FMT)
• Engineered Microbial Consortia
• Next-Generation Probiotics
• Prebiotics & Postbiotics
• Phage-Based Therapies
Target Areas Covered:
• Gut Microbiome
• Oral Microbiome
• Skin Microbiome
• Vaginal Microbiome
• Respiratory Microbiome
• Neural & Immune Microbiome
Technologies Covered:
• Genomics & Sequencing Technologies
• Computational Modeling & AI
• Synthetic Biology Platforms
• Precision Microbiome Editing
• In Vitro Microbiome Culturing
• Omics-Based Profiling Tools
Applications Covered:
• Gastrointestinal Disorders
• Metabolic Diseases
• Immune & Autoimmune Disorders
• Skin Disorders
• Mental Health & Neurodegeneration
• Infectious Diseases
End Users Covered:
• Pharmaceutical Companies
• Biotechnology Firms
• Research & Clinical Labs
• Hospitals & Treatment Centers
• CROs & Academic Institutions
• Specialty Wellness Clinics
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Microbiome Therapies Market, By Therapy Type
5.1 Introduction
5.2 Live Biotherapeutic Products (LBPs)
5.3 Fecal Microbiota Transplantation (FMT)
5.4 Engineered Microbial Consortia
5.5 Next-Generation Probiotics
5.6 Prebiotics & Postbiotics
5.7 Phage-Based Therapies
6 Global Microbiome Therapies Market, By Target Area
6.1 Introduction
6.2 Gut Microbiome
6.3 Oral Microbiome
6.4 Skin Microbiome
6.5 Vaginal Microbiome
6.6 Respiratory Microbiome
6.7 Neural & Immune Microbiome
7 Global Microbiome Therapies Market, By Technology
7.1 Introduction
7.2 Genomics & Sequencing Technologies
7.3 Computational Modeling & AI
7.4 Synthetic Biology Platforms
7.5 Precision Microbiome Editing
7.6 In Vitro Microbiome Culturing
7.7 Omics-Based Profiling Tools
8 Global Microbiome Therapies Market, By Application
8.1 Introduction
8.2 Gastrointestinal Disorders
8.3 Metabolic Diseases
8.4 Immune & Autoimmune Disorders
8.5 Skin Disorders
8.6 Mental Health & Neurodegeneration
8.7 Infectious Diseases
9 Global Microbiome Therapies Market, By End User
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Biotechnology Firms
9.4 Research & Clinical Labs
9.5 Hospitals & Treatment Centers
9.6 CROs & Academic Institutions
9.7 Specialty Wellness Clinics
10 Global Microbiome Therapies Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Seres Therapeutics
12.2 Ferring Pharmaceuticals
12.3 Vedanta Biosciences
12.4 Finch Therapeutics
12.5 Synthetic Biologics
12.6 4D Pharma
12.7 BiomeBank
12.8 Evelo Biosciences
12.9 Enterome
12.10 Rebiotix (Ferring)
12.11 Takeda
12.12 Johnson & Johnson
12.13 Novartis
12.14 GSK
12.15 Pfizer
12.16 Roche
12.17 Merck & Co.
List of Tables
1 Global Microbiome Therapies Market Outlook, By Region (2024-2032) ($MN)
2 Global Microbiome Therapies Market Outlook, By Therapy Type (2024-2032) ($MN)
3 Global Microbiome Therapies Market Outlook, By Live Biotherapeutic Products (LBPs) (2024-2032) ($MN)
4 Global Microbiome Therapies Market Outlook, By Fecal Microbiota Transplantation (FMT) (2024-2032) ($MN)
5 Global Microbiome Therapies Market Outlook, By Engineered Microbial Consortia (2024-2032) ($MN)
6 Global Microbiome Therapies Market Outlook, By Next-Generation Probiotics (2024-2032) ($MN)
7 Global Microbiome Therapies Market Outlook, By Prebiotics & Postbiotics (2024-2032) ($MN)
8 Global Microbiome Therapies Market Outlook, By Phage-Based Therapies (2024-2032) ($MN)
9 Global Microbiome Therapies Market Outlook, By Target Area (2024-2032) ($MN)
10 Global Microbiome Therapies Market Outlook, By Gut Microbiome (2024-2032) ($MN)
11 Global Microbiome Therapies Market Outlook, By Oral Microbiome (2024-2032) ($MN)
12 Global Microbiome Therapies Market Outlook, By Skin Microbiome (2024-2032) ($MN)
13 Global Microbiome Therapies Market Outlook, By Vaginal Microbiome (2024-2032) ($MN)
14 Global Microbiome Therapies Market Outlook, By Respiratory Microbiome (2024-2032) ($MN)
15 Global Microbiome Therapies Market Outlook, By Neural & Immune Microbiome (2024-2032) ($MN)
16 Global Microbiome Therapies Market Outlook, By Technology (2024-2032) ($MN)
17 Global Microbiome Therapies Market Outlook, By Genomics & Sequencing Technologies (2024-2032) ($MN)
18 Global Microbiome Therapies Market Outlook, By Computational Modeling & AI (2024-2032) ($MN)
19 Global Microbiome Therapies Market Outlook, By Synthetic Biology Platforms (2024-2032) ($MN)
20 Global Microbiome Therapies Market Outlook, By Precision Microbiome Editing (2024-2032) ($MN)
21 Global Microbiome Therapies Market Outlook, By In Vitro Microbiome Culturing (2024-2032) ($MN)
22 Global Microbiome Therapies Market Outlook, By Omics-Based Profiling Tools (2024-2032) ($MN)
23 Global Microbiome Therapies Market Outlook, By Application (2024-2032) ($MN)
24 Global Microbiome Therapies Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
25 Global Microbiome Therapies Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
26 Global Microbiome Therapies Market Outlook, By Immune & Autoimmune Disorders (2024-2032) ($MN)
27 Global Microbiome Therapies Market Outlook, By Skin Disorders (2024-2032) ($MN)
28 Global Microbiome Therapies Market Outlook, By Mental Health & Neurodegeneration (2024-2032) ($MN)
29 Global Microbiome Therapies Market Outlook, By Infectious Diseases (2024-2032) ($MN)
30 Global Microbiome Therapies Market Outlook, By End User (2024-2032) ($MN)
31 Global Microbiome Therapies Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
32 Global Microbiome Therapies Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
33 Global Microbiome Therapies Market Outlook, By Research & Clinical Labs (2024-2032) ($MN)
34 Global Microbiome Therapies Market Outlook, By Hospitals & Treatment Centers (2024-2032) ($MN)
35 Global Microbiome Therapies Market Outlook, By CROs & Academic Institutions (2024-2032) ($MN)
36 Global Microbiome Therapies Market Outlook, By Specialty Wellness Clinics (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
